Table 3.
Comparison of single-photon and coincidence-detection nuclear medicine technologies as applied to breast imaging.
| MBI | MBI | PEM | DbPET | |
|---|---|---|---|---|
| (Dual-head CZT-based) | (BSGI) | |||
| Primary proposed clinical indications | Preoperative evaluation | Preoperative evaluation | ||
| Monitoring response to neoadjuvant therapy | Monitoring response to neoadjuvant therapy | |||
| Patients with contraindications to MRI | Patients with contraindications to MRI | |||
| Screening in dense breasts (at low radiation dose) | ||||
| Radiopharmaceutical | Tc-99m sestamibi or Tc-99m tetrofosmin | F-18 FDG | ||
| Administered activityt1n1 | 300 MBq | 740–1110 MBq | 370 MBq | 370 MBq |
| Fasting period prior to imaging | None | None | 4–6 h | 4–6 h |
| Wait period between injection and imaging | 5 min | 5 min | 40–60 min | 40–60 min |
| Acquisition duration | 10 min/view × 4 views | 10 min/view × 4 views | 10 min/view × 4 views | Variable |
| Biopsy guidance | In development | FDA-approved | FDA-approved | Not available |
| FOV | 20 × 16 cm or | 20 cm by 15 cm or | 24 × 16 cm | Variable |
| 24 × 16 cm | 25 cm × 20 cm | |||
| Standardized interpretive criteria | Yes (Refs. 219 and 220) | Yes (Ref. 173) | Yes (Ref. 221) | No |
1
Although a range of values are used in clinical and research settings, typical administered doses used in clinical exams are given.